Sort   by:  
 Page size 
MetabolomicsSpermine is a natural suppressor of AR signaling in castration-resistant prostate cancer
In castration-resistant prostate cancer (CRPC), clinical response to androgen receptor (AR) antagonists is limited mainly due to AR-variants expression and restored AR signaling. The metabolite spermine is most abundant in prostate and it decreases as prostate cancer progresses, but its functions re...
2023-10-11 | MTBLS8034 | MetaboLights
TranscriptomicsSRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer
The neuroendocrine (NE) phenotype is associated with the development of metastatic castration-resistant prostate cancer (CRPC). Our objective was to characterize the molecular features of the NE phenotype in CRPC. Expression of chromogranin A (CHGA), synaptophysin (SYP), androgen receptor (AR), and ...
ORGANISM(S): Homo sapiens 
2015-06-24 | E-GEOD-66187 | biostudies-arrayexpress
GenomicsPersistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions
The androgen receptor (AR) is a ligand-inducible transcription factor that mediates androgen action in target tissues. Upon ligand binding, the AR binds to thousands of genomic loci and activates a cell-type specific gene program. Prostate cancer growth and progression depend on androgen-induced AR ...
ORGANISM(S): Homo sapiens 
2012-10-02 | E-GEOD-40050 | biostudies-arrayexpress
TranscriptomicsIdentification of EP4 as a Potential Target for the Treatment of Castration-Resistant Prostate Cancer Using a Novel Xenograft Model
More effective therapeutic approaches for castration-resistant prostate cancer (CRPC) are urgently needed, thus reinforcing the need to understand how prostate tumors progress to castration resistance. We have established a novel mouse xenograft model of prostate cancer, KUCaP-2, which expresses the...
ORGANISM(S): Homo sapiens 
2010-06-08 | E-GEOD-21887 | biostudies-arrayexpress
TranscriptomicsLNCaP Atlas: Gene expression associated with in vivo progression to castration-recurrent prostate cancer
Background: There is no cure for castration-recurrent prostate cancer (CRPC) and the mechanisms underlying this stage of the disease are unknown. Methods: We analyzed the transcriptome of human LNCaP prostate cancer cells as they progress to CRPC in vivo using replicate LongSAGE libraries. We refer ...
ORGANISM(S): Homo sapiens 
2010-09-26 | E-GEOD-18402 | biostudies-arrayexpress
ProteomicsPhospo-proteomic profiling of Castration Resistant Prostate Cancer
The integration of diverse ‘omic’ datasets will increase our understanding of the key signaling pathways that drive disease. Here, we used clinical tissue cohorts corresponding to lethal metastatic castration resistant prostate cancer (CRPC) obtained at rapid autopsy to integrate mutational, transcr...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2017-03-29 | MSV000080776 | MassIVE
ModelsTreatment of Castration-Resistant Prostate Cancer
Background: Prostate cancer is one of the most prevalent cancers in males in the United States and amongst the leading causes of cancer related deaths. A particularly virulent form of this disease is castration-resistant prostate cancer (CRPC), where patients no longer respond to medical or surgica...
8048 | Cell Collective
GenomicsThe cistrome and transcriptome landscape of androgen receptor splice variants in castration-resistant prostate cancer cells
The spliced variant forms of androgen receptor (AR-Vs) have been identified recently in castration-resistant prostate cancer (CRPC) cell lines and clinical samples. Here we identified the cistrome and transcriptome landscape of AR-Vs in CRPC cell lines and determine the clinical significance of AR v...
ORGANISM(S): Homo sapiens 
2014-09-10 | E-GEOD-58478 | biostudies-arrayexpress
TranscriptomicsExpression data from docetaxel-resistant prostate cancer cell lines
Docetaxel-based chemotherapy is the standard first-line therapy in metastatic castration-resistant prostate cancer. However, most patients eventually develop resistance to this treatment. The aim of the study was to identify key molecular genes and networks associated with docetaxel resistance in 2 ...
ORGANISM(S): Homo sapiens 
2012-01-01 | E-GEOD-33455 | biostudies-arrayexpress
TranscriptomicsHes6 drives a network with therapeutic potential in castrate-resistant prostate cancer
Castrate-resistant prostate cancer (CRPC) is poorly characterized and heterogeneous and while the androgen receptor (AR) is of singular importance in early prostate cancer, other factors such as c-Myc and the E2F family also play a role in later stage disease. Hes6 is a transcription co-factor that ...
ORGANISM(S): Homo sapiens 
2014-04-17 | E-GEOD-36526 | biostudies-arrayexpress
Sort   by:  
 Page size